Pancreastatin

More Novel Tests

References

Bandyopadhyay, G. K. (2015). Pancreastatin-dependent inflammatory signaling mediates obesity-induced insulin resistance. Diabetes, 64(1), 104-116. Calhoun, K. (2003). Serum peptide profiles in patients with carcinoid tumors. American Journal of Surgery, 186(1), 28-31. Chang, J. (2026). Risk factors and prognosis of peritoneal metastases in small bowel neuroendocrine tumor patients. Annals of Surgical Oncology, 33(1), 265-274. Funakoshi, A. (1990). Elevated plasma levels of pancreastatin (PST) in patients with non-insulin-dependent diabetes mellitus (NIDDM). Regulatory Peptides, 30(2), 159-164. Garg, R. (2023). Pancreastatin inhibitor PSTi8 ameliorates insulin resistance by decreasing fat accumulation and oxidative stress in high-fat diet-fed mice. Amino Acids, 55(11), 1587-1600. Garg, R. (2023). Pancreastatin inhibitor PSTi8 ameliorates streptozotocin-induced diabetes by suppressing hepatic glucose production. European Journal of Pharmacology, 944, 175559. Hossain, Z. (2018). Discovery of pancreastatin inhibitor PSTi8 for the treatment of insulin resistance and diabetes: studies in rodent models of diabetes mellitus. Scientific Reports, 8(1), 8715. Ito, T. (2012). Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors? Pancreas, 41(4), 505-507. Maj, M. (2025). A complex role of chromogranin A and its peptides in inflammation, autoimmunity, and infections. Frontiers in Immunology, 16, 1567874. O'Connor, D. T. (2005). Pancreastatin: multiple actions of human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. The Journal of Clinical Endocrinology & Metabolism, 90(9), 5414-5425. Raines, D. (2012). A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas, 41(4), 508-511. Rustagi, S. (2013). Serum pancreastatin: the next predictive neuroendocrine tumor marker. Journal of Surgical Oncology, 108(2), 126-128. Sánchez-Margalet, V. (2010). Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin. Regulatory Peptides, 161(1-3), 8-14. Sánchez-Margalet, V. (1998). Increased plasma pancreastatin-like levels in gestational diabetes: correlation with catecholamine levels. Diabetes Care, 21(11), 1951-1954. Sánchez-Margalet, V. (1995). Increased plasma pancreastatin-like immunoreactivity levels in non-obese patients with essential hypertension. Journal of Hypertension, 13(2), 251-258. Sherman, S. K. (2014). Pancreastatin predicts survival in neuroendocrine tumors. Annals of Surgical Oncology, 21(9), 2971-1980. Stronge, R. L. (2008). A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours. Annals of Clinical Biochemistry, 45(6), 560-566. Syversen, U. (1993). Chromogranin A and pancreastatin-like immunoreactivity in serum gastrinoma patients. Acta Oncologica, 32(2), 161-165. Unal Kocabas, G. (2024). The association of plasma pancreastatin levels with insulin resistance in patients with gestational diabetes mellitus. Obstetric Medicine, 17(4), 221-225. Woltering, E. A. (2016). Elevated plasma pancreastatin, but not chromogranin A, predicts survival in neuroendocrine tumors of the duodenum. Journal of the American College of Surgeons, 222(4), 534-542.